Drug intelligence / Profile preview

COVIDARON

Development stage: Preclinical
Lead developer: AronPharma

Overview

COVIDARON is a natural nutraceutical developed by AronPharma, specifically designed to provide immunomodulatory and antiviral support for individuals affected by SARS-CoV-2. Part of AronPharma's R&D pipeline, the product is intended to assist in the recovery and therapy of patients by strengthening the immune system and mitigating the physiological impacts of the virus. It leverages natural bioactive compounds, likely including standardized polyphenols, to support the body's defense mechanisms during and after infection. The project (POIR.01.01.01-00-0014/21) is co-financed by the National Centre for Research and Development in Poland.

Brand names: COVIDARON

Beyond the preview

Go deeper on COVIDARON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIDARON.

Explore the full profile